Novartis Reports Results of Kisqali in Second Phase P-III MONALEESA-3 Study for HR+/HER2- Advanced Breast Cancer in Women
Shots:
- The P-III MONALEESA-3 study involves assessing of Kisqali (ribociclib) + fulvestrant in postmenopausal women with HR+/HER2- advanced or m-breast cancer
- The second phase of P-III MONALEESA-3 study resulted in meeting its 2EPs of OS with no new observed safety signals and consistent AEs with the previous P-III study results. These results follow MONALEESA-7 study results which demonstrated improved OS in patients with HR+/HER2- advanced breast cancer in pre/peri-menopausal women
- Kisqali is the CDK4/6 inhibitor- being evaluated in P-III NATALEE study with endocrine therapy in the adjuvant treatment of HR+/HER2- early breast cancer and has received FDA & EMA’s approval in Mar’2017 and Aug’2017 respectively
Click here to read full press release/ article | Ref: Novartis | Image: Twitter
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com